Nasdaq · Biotech stocks database

IVA — Inventiva S.A.

IVA (Inventiva S.A.) stock: $3.78, $893.1M market cap, $227.5M cash, $728.0M EV, $1.52B fully diluted market cap. Next expected readout: Sep-27. Lead program: IVA337 (NASH - Nonalcoholic Steatohepatitis), Phase 3. Data from Fully Diluted's biotech stocks database.

Share price

$3.78

Market cap

$893.1M

Cash

$227.5M

Enterprise value

$728.0M

Balance sheet

Cash	$227.5M
Debt	$62.4M
Net cash	$165.1M
Enterprise value	$728.0M
Basic shares	236.0M shares
Fully diluted shares	401.0M shares
Fully diluted market cap	$1,515.6M
Cash per share	$0.96

Cash figures as of 2026-06-05. Database snapshot: 2026-09-21.

Price history

Loading IVA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 11 - Dec 23	IVA337	Phase 3	NASH - Nonalcoholic Steatohepatitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	IVA337
Lead indication	NASH - Nonalcoholic Steatohepatitis
Lead phase	Phase 3
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04849728	Phase 3	Active, not recruiting	Sponsor	Inventiva Pharma	—	NASH - Nonalcoholic Steatohepatitis	—
NCT05651724	Not disclosed	Recruiting	Collaborator	Julius Clinical	NVO	MASH; MASLD; MASH With Fibrosis	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Inventiva Pharma on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	3,606,656	+1,432,258	0.64%	2026-08-14
Ikarian Capital	1,129,101	-300,000	0.68%	2026-08-14
RTW Investments	0	-1,298,702	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego